1. LUNG TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

2. NUMBER OF LUNG TRANSPLANTS REPORTED BY YEAR AND PROCEDURE TYPE 13 1546 83 189 418 708 922 1089 1229 1368 1377 1464 1457 1477 1564 1602 1767 1703 ISHLT 2005 NOTE: This figure includes only the lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as representing changes in the number of lung transplants performed worldwide. J Heart Lung Transplant 2005;24: 945-982

3. AVERAGE CENTER VOLUME Lung Transplants: January 1, 1998 - June 30, 2004 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

4. DISTRIBUTION OF TRANSPLANTS BY CENTER VOLUME Lung Transplants: January 1, 1998 - June 30, 2004 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

5. LUNG TRANSPLANTS: Donor Age by Year of Transplant ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

6. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS (1/1985-6/2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

7. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS BY ERA ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

8. LUNG TRANSPLANTATION Adult Recipients ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

9. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS (1/1985-6/2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

10. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS BY ERA ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

11. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival (Transplants: January 1994 - June 2003) P < 0.0001 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

12. ADULT LUNG TRANSPLANTATION: Indications (1/1995-6/2004) DIAGNOSISSLT (N = 6,731)BLT (N = 6,276)TOTAL (N = 13,007) COPD/Emphysema3,541 (53%)1,462 (23%)5,003 (38%) Idiopathic Pulmonary Fibrosis1,618 (24%)639 (10.0%)2,257 (17%) Cystic Fibrosis151 (2.2%)2,002 (32%)2,153 (17%) Alpha-1554 (8.2%)571 (9.1%)1,125 (8.6%) Primary Pulmonary Hypertension79 (1.2%)436 (6.9%)515 (4%) Sarcoidosis157 (2.3%)166 (2.6%)323 (2.5%) Bronchiectasis45 (0.7%)309 (4.9%)354 (2.7%) LAM55 (0.8%)83 (1.3%)138 (1.1%) Congenital Heart Disease13 (0.2%)118 (1.9%)131 (1.0%) Re-Transplant: Obliterative Bronchiolitis 74 (1.1%)58 (0.9%)132 (1.0%) Obliterative Bronchiolitis (Not Re-Transplant) 39 (0.6%)80 (1.3%)119 (0.9%) Re-Transplant: Not Obliterative Bronchiolitis 55 (0.8%)46 (0.7%)101 (0.8%) Connective Tissue Disease34 (0.5%)31 (0.5%)65 (0.5%) Histiocytosis X20 (0.3%)19 (0.3%)39 (0.3%) Cancer7 (0.1%)14 (0.2%)21 (0.2%) Other289 (4.3%)242 (3.8%)509 (4.1%) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

13. ADULT LUNG TRANSPLANTATION: Distribution of Procedure Type for Major Indications (1990-2003) ISHLT 2005 Year of TX Alpha-1COPDCystic FibrosisIPFPPH Double/ bilateral SingleDouble/ bilateral SingleDouble/ bilateral SingleDouble/ bilateral SingleDouble/ bilateral Single 199027.872.221.978.194.75.31.898.215.484.6 199117.382.714.285.895.84.214.185.923.476.6 199223.376.716.583.597.03.09.290.826.973.1 199332.767.316.383.794.85.216.783.352.347.7 199432.767.317.083.085.514.514.285.860.539.5 199540.259.818.981.189.310.726.573.587.712.3 199643.856.225.274.886.413.626.373.781.019.0 199743.756.325.574.592.77.321.678.483.316.7 199845.354.727.772.392.57.518.881.378.821.2 199945.055.027.972.190.79.322.377.783.716.3 200056.743.327.872.295.24.829.071.091.38.7 200157.642.426.673.493.76.325.374.784.016.0 200253.546.536.064.096.04.034.765.381.418.6 200360.040.037.962.195.84.237.962.187.812.2 J Heart Lung Transplant 2005;24: 945-982

14. ADULT LUNG TRANSPLANTATION Procedure Type within Indication, by Year J Heart Lung Transplant 2005;24: 945-982 2005

15. ADULT LUNG TRANSPLANTATION: Indications for Single Lung Transplants (Transplants: January 1995 - June 2004) ISHLT 2005 *Other includes: Sarcoidosis: 2% Bronchiectasis: 0.7% Congenital Heart Disease: 0.2% LAM: 0.8% OB (non-ReTx): 0.6% Miscellaneous:5% J Heart Lung Transplant 2005;24: 945-982

16. ADULT LUNG TRANSPLANTATION: Indications for Bilateral/Double Lung Transplants (Transplants: January 1995 - June 2004) ISHLT 2005 *Other includes: Re-Tx: 2% Congenital Heart Disease: 2% LAM: 1.3% OB (non-ReTx): 1.3% Miscellaneous:5% J Heart Lung Transplant 2005;24: 945-982

17. ADULT LUNG TRANSPLANTATION Indications By Year (%) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

18. ADULT LUNG TRANSPLANTATION Indications By Year (Number) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

19. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: January 1988 – June 2003) Survival comparisons by era 1988-94 vs. 1995-99: p = 0.01 1988-94: vs. 2000-6/03: p <0.0001 1995-99 vs. 2000-6/03: p <0.0001 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

20. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: January 1990 – June 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

21. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Gender (Transplants: January 1994 – June 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

22. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis (Transplants: January 1994 – June 2003) Year ALPHA-1 (N=1,127) CF (N=1,934) COPD (N=4,888) IPF (N=2,058) PPH (N=553) SARCOIDOSIS (N=314) 175.780.681.369.465.467.6 360.265.263.453.755.554.1 550.553.848.442.146.147.3 742.244.735.332.837.142.2 1031.332.119.015.425.532.8 Survival comparisons COPD vs. IPF: p < 0.0001Alpha-1 vs. CF: p = 0.0248 Alpha-1 vs. IPF: p < 0.0001Alpha-1 vs. PPH: p = 0.0021 CF vs. COPD: p = 0.0006CF vs. IPF: p < 0.0001 CF vs. PPH: p < 0.0001CF vs. Sarcoidosis: p = 0.0007 Note: Other comparisons are not statistically different. ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

23. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 3 Months (Transplants: January 1994 – June 2003) Year ALPHA-1 (N=905) CF (N= 1,516) COPD (N= 4,089) IPF (N= 1,575) PPH (N= 374) SARCOIDOSIS (N=225) 187.891.289.985.289.584.0 369.773.870.165.975.967.3 558.560.953.651.863.158.8 748.950.739.140.350.752.4 1036.3 21.018.934.940.8 Survival comparisons Alpha-1 vs. IPF: p = 0.0015Alpha-1 vs. COPD: p = 0.0073 CF vs. COPD: p < 0.0001CF vs. IPF: p < 0.0001 PPH vs. COPD: p = 0.0005PPH vs. IPF: p = 0.0002 Note: Other comparisons are not statistically different. ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

24. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 1 Year (Transplants: January 1994 – June 2003) Year ALPHA-1 (N=769) CF (N=1,300) COPD (N= 3,468) IPF (N=1,273) PPH (N= 322) SARCOIDOSIS (N=180) 1100.0 379.380.777.977.484.880.1 566.6 59.660.770.570.0 755.755.443.447.356.762.4 1041.339.723.322.239.048.6 Survival comparisons Alpha-1 vs. IPF: p = 0.0103Alpha-1 vs. COPD: p < 0.0001 CF vs. COPD: p < 0.0001CF vs. IPF: p = 0.0012 PPH vs. COPD: p < 0.0001PPH vs. IPF: p = 0.0017 COPD vs. Sarcoidosis: p = 0.0102IPF vs. Sarcoidosis: p = 0.0408 Note: Other comparisons are not statistically different. ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

25. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis (Transplants: January 1994 – June 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

26. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 3 Months (Transplants: January 1994 – June 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

27. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 1 Year (Transplants: January 1994 – June 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

28. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival for Eisenmengers Syndrome (Transplants: January 1990 – June 2003) ISHLT 2005 N at risk at 5 years = 33 N at risk at 5 years = 15 J Heart Lung Transplant 2005;24: 945-982

29. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Procedure Type (Transplants: January 1990 – June 2003) Diagnosis: Alpha-1 Antitrypsin Deficiency P = 0.0007 ISHLT 2005 N at risk at 10 years is 44 for Single Lung and 23 for Double Lung. J Heart Lung Transplant 2005;24: 945-982

30. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Procedure Type and Median Age (Transplants: January 1990 – June 2003) Diagnosis: Alpha-1 Antitrypsin Deficiency ISHLT 2005 N at risk at 5 years: Single Lung, <50 = 140; Double Lung, <50 = 126; Single Lung, 50+ = 97; Double Lung, 50+ = 45 p = 0.22 J Heart Lung Transplant 2005;24: 945-982

31. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2003) Diagnosis: Emphysema/COPD P < 0.0001 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

32. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Age (Transplants: January 1990 – June 2003) Diagnosis: Emphysema/COPD P < 0.0001 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

33. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2003) Diagnosis: Idiopathic Pulmonary Fibrosis P = 0.5 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

34. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2003) Diagnosis: Primary Pulmonary Hypertension P = 0.3 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

35. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2003) Diagnosis: Emphysema/COPD, Single Lung ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

36. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2003) Diagnosis: Emphysema/COPD, Double/Bilateral Lung ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

37. ADULT LUNG TRANSPLANTATION Actual Survival by Procedure Type and Era (Transplants: January 1990 – December 1999) Diagnosis: Emphysema/COPD, Double/Bilateral Lung ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

38. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2003) Diagnosis: Idiopathic Pulmonary Fibrosis, Single Lung ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

39. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2003) Diagnosis: Idiopathic Pulmonary Fibrosis, Double/Bilateral Lung ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

40. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Donor CMV status/Recipient CMV status (Transplants: October 1999 – June 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

41. ADULT LUNG TRANSPLANTS (1995-6/2003) Risk Factors for 1 Year Mortality (N=11,291) ISHLT 2005 *Other = All diagnoses other than COPD, PPH, IPF, CF, bronchiectasis, Alpha-1 antitrypsin deficiency, and LAM. J Heart Lung Transplant 2005;24: 945-982

42. ADULT LUNG TRANSPLANTS (1995-6/2003) Risk Factors for 1 Year Mortality (N=11,291) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

43. ADULT LUNG TRANSPLANTS (1995-6/2003) Risk Factors for 1 Year Mortality (N=11,291) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

44. ADULT LUNG TRANSPLANTS (1995-6/2003) Borderline Significant Risk Factors for 1 Year Mortality (N=11,291) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

45. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

46. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Recipient Age ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

47. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Donor Age ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

48. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Donor Weight ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

49. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Pre-Transplant Recipient BMI ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

50. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Center volume ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

51. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality FEV1 (% predicted) in Recipients with Idiopathic Pulmonary Fibrosis ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

52. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Pre-Transplant Bilirubin ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

53. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 1 Year Mortality Recipient Pulmonary Vascular Resistance ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

54. ADULT LUNG TRANSPLANTS (1995-6/2003) Factors Not Significant for 1 Year Mortality Recipient factors: pCO 2, PA pressures, transfusions, recent infection requiring IV drug therapy, diabetes, sternotomy, dialysis, FVC, creatinine, PRA, cardiac output, chronic steroid use, weight, height Donor factors: History of hypertension, history of cancer, cause of death, height, BMI Transplant factors: Height ratio, BMI ratio, ischemia time ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

55. ADULT LUNG TRANSPLANTS (1/1995-6/2003) 1-Year Predicted Survival – Hypothetical Case #1 ISHLT 2005 Other characteristics: ABO identical, primary transplant, no IV inotropes, no prior thoracotomy, 3 HLA mismatches, not hospitalized, no history of malignancy, no donor clinical infection, no CMV MM, no donor history of diabetes J Heart Lung Transplant 2005;24: 945-982

56. ADULT LUNG TRANSPLANTS (1/1995-6/2003) 1-Year Predicted Survival – Hypothetical Case #2 ISHLT 2005 Other characteristics: ABO identical, primary transplant, no IV inotropes, no prior thoracotomy, 3 HLA mismatches, not hospitalized, no history of malignancy, no donor clinical infection, no CMV MM, no donor history of diabetes J Heart Lung Transplant 2005;24: 945-982

57. ADULT LUNG TRANSPLANTS (1/1995-6/2003) 1-Year Predicted Survival – Hypothetical Case #3 ISHLT 2005 Other characteristics: ABO identical, primary transplant, no IV inotropes, no prior thoracotomy, 3 HLA mismatches, not hospitalized, no history of malignancy, no donor clinical infection, no CMV MM, no donor history of diabetes J Heart Lung Transplant 2005;24: 945-982

58. ADULT LUNG TRANSPLANTS (1/1995-6/2003) 1-Year Predicted Survival – Hypothetical Case #4 ISHLT 2005 Other characteristics: ABO identical, primary transplant, no IV inotropes, no prior thoracotomy, 3 HLA mismatches, not hospitalized, no history of malignancy, no donor clinical infection, no CMV MM, no donor history of diabetes J Heart Lung Transplant 2005;24: 945-982

59. ADULT LUNG TRANSPLANTS (1995-6/1999) Risk Factors for 5 Year Mortality (N=5,637) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

60. ADULT LUNG TRANSPLANTS (1995-6/1999) Risk Factors for 5 Year Mortality (N=5,637) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

61. ADULT LUNG TRANSPLANTS (1995-6/1999) Risk Factors for 5 Year Mortality (N=5,637) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

62. ADULT LUNG TRANSPLANTS (1995-6/1999) Borderline Significant Risk Factors for 5 Year Mortality (N=5,637) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

63. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

64. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Recipient Age ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

65. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Donor Age ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

66. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Pre-Transplant Recipient BMI ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

67. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Donor Weight ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

68. ADULT LUNG TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Pre-Transplant Bilirubin ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

69. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Recipient PA Systolic Pressure ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

70. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Pre-Transplant Creatinine ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

71. ADULT LUNG TRANSPLANTS (1995-6/1999) Factors Not Significant for 5 Year Mortality Recipient factors: Hospitalized, chronic steroid use, transfusions, history of malignancy, cardiac output, PRA, FVC, FEV1, PCO 2, pulmonary vascular resistance, dialysis, recent infection requiring IV drug therapy Donor factors: Clinical infection, history of hypertension, history of cancer, history of diabetes, height Transplant factors: CMV mismatch, ischemia time, transplant center volume ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

72. ADULT LUNG TRANSPLANTS (1995-6/1999) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=4,028) ISHLT 2005 *Other = All diagnoses other than COPD, PPH, IPF, CF, bronchiectasis, Alpha-1 antitrypsin deficiency, and LAM. J Heart Lung Transplant 2005;24: 945-982

73. ADULT LUNG TRANSPLANTS (1995-6/1999) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=4,028) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

74. ADULT LUNG TRANSPLANTS (1995-6/1999) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=4,028) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

75. ADULT LUNG TRANSPLANTS (1995-6/1999) Borderline Significant Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=4,028) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

76. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

77. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient Age ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

78. ADULT LUNG TRANSPLANTS (1/1995-6/1999) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Donor Age ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

79. ADULT LUNG TRANSPLANTS (1995-6/1999) Factors Not Significant for Conditional 5 Year Mortality Recipient factors: Ventilator, inotropes, hospitalized at transplant, pCO 2, gender, chronic steroid use, transfusions, history of malignancy, PRA, repeat transplant, FEV1, FVC, height, weight, PA pressures, O 2 required, bilirubin, creatinine, recent infection requiring use of IV drug therapy, thoracotomy, cardiac output Donor factors: Gender, clinical infection, history of hypertension, history of cancer, history of diabetes, height, weight ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

80. ADULT LUNG TRANSPLANTS (1995-6/1999) Factors Not Significant for Conditional 5 Year Mortality Transplant factors: ABO compatibility, CMV mismatch, transplant center volume Post-transplant factors: Stroke prior to discharge, prolonged graft dysfunction prior to discharge, treated for rejection prior to discharge ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

81. ADULT LUNG RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April 1994 – June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

82. ADULT LUNG RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: April 1994 – June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

83. ADULT LUNG RECIPIENTS: Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

84. ADULT LUNG RECIPIENTS Induction Immunosuppression (Follow-ups: January 2002 - June 2004) Analysis limited to patients receiving prednisone ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

85. ADULT LUNG RECIPIENTS Induction Immunosuppression (Follow-ups: January 2000 - December 2003) Analysis limited to patients receiving prednisone ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

86. SURVIVAL BY INDUCTION USAGE For Adult Lung Recipients (Transplants: April 1994-June 2003) Conditional on survival to 14 days ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

87. SURVIVAL BY INDUCTION USAGE For Adult Lung Recipients (Transplants: January 2000-June 2003) Conditional on Survival to 14 days ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

88. ADULT LUNG RECIPIENTS Maintenance Immunosuppression At Time of Follow-up For follow-ups between January 2001 through June 2004 Analysis limited to patients receiving prednisone NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

89. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2001 through June 2004 Analysis limited to patients receiving prednisone 1 Year Follow-up (N = 1,928)5 Year Follow-up (N = 865) NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

90. ADULT LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2001 through June 2003 Conventional Combinations Analysis limited to patients receiving prednisone ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

91. ADULT LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2001 through June 2003 Other Combinations Analysis limited to patients receiving prednisone ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

92. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Type of Induction (Transplants: January 1, 2000 - June 30, 2003) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

93. NUMBER OF REJECTION EPISODES FOR ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Type of Induction (Transplants: January 1, 2000 - June 30, 2003) Overall: no induction vs. polyclonal (p < 0.0001); no induction vs. IL2R (p = 0.0110); polyclonal vs. IL2R (p = 0.0355). 18-34: no induction vs. polyclonal (p = 0.002); polyclonal vs. IL2R (p = 0.019). 50-64: no induction vs. polyclonal (p = 0.022) Females: no induction vs. polyclonal (p = 0.04); no induction vs. IL2R (p = 0.04). Males: no induction vs. polyclonal (p = 0.0003); polyclonal vs. IL2R (p = 0.011) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

94. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Maintenance Immunosuppression (Transplants: January 1, 2000 - June 30, 2003) Overall: CyA + MMF vs. TAC + MMF (p = 0.0007); CyA + AZA vs. TAC + MMF (p < 0.0001); CyA + AZA vs. TAC + AZA (p = 0.0002). 35-49: CyA + MMF vs. TAC + MMF (p = 0.017); CyA + AZA vs. TAC + MMF (p = 0.0004); CyA + AZA vs. TAC + AZA (p = 0.023). 50-64: CyA + MMF vs. TAC + MMF (p = 0.037); CyA + AZA vs. TAC + MMF (p < 0.0001); CyA + MMF vs. CyA + AZA (p = 0.045); CyA + AZA vs. TAC + AZA (p = 0.0003). 65+: CyA + AZA vs. TAC + MMF (p = 0.035); CyA + MMF vs. TAC + MMF (p = 0.035). Females: CyA + AZA vs. TAC + MMF (p = 0.002); CyA + AZA vs. TAC + AZA (p = 0.014). Males: CyA + MMF vs. TAC + MMF (p = 0.0007); CyA + AZA vs. TAC + MMF (p < 0.0001); CyA + AZA vs. TAC + AZA (p = 0.005); TAC + MMF vs. TAC + AZA (p = 0.04) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

95. NUMBER OF REJECTION EPISODES FOR ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Maintenance Immunosuppression (Transplants: January 1, 2000 - June 30, 2003) Overall: CyA + MMF vs. CyA + AZA (p = 0.0015); CyA + AZA vs. TAC + MMF (p < 0.0001); TAC + MMF vs. TAC + AZA (p = 0.0257). 18-34: CyA + MMF vs. CyA + AZA (p = 0.046); CyA + AZA vs. TAC + MMF (p = 0.014). 50-64: CyA + MMF vs. CyA + AZA (p = 0.013); CyA +AZA vs. TAC + MMF (p = 0.002); CyA + AZA vs. TAC + AZA (p = 0.02). Female: CyA + AZA vs. TAC + MMF (p = 0.0005). Male: CyA + AZA vs. TAC + MMF (p = 0.04); CyA + MMF vs. CyA + AZA (p = 0.007) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

96. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

97. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 and 5 Years Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

98. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 8 Years Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

99. FREEDOM FROM BRONCHIOLITIS OBLITERANS For Adult Lung Recipients (Follow-ups: April 1994-June 2004) Conditional on Survival to 90 days ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

100. FREEDOM FROM BRONCHIOLITIS OBLITERANS STRATIFIED BY INDUCTION USE For Adult Lung Recipients (Follow-ups: April 1994-June 2004) Conditional on Survival to 90 days ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

101. FREEDOM FROM SEVERE RENAL DYSFUNCTION * For Adult Lung Recipients (Follow-ups: April 1994-June 2004) * Severe renal dysfunction = Creatinine > 2.5 mg/dl, dialysis or renal transplant ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

102. MALIGNANCY POST-LUNG TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April 1994 - June 2004) Malignancy/Type1-Year Survivors5-Year Survivors7-Year Survivors No Malignancy 7025 (96.1%)1427 (87%)553 (81.7%) Malignancy (all types combined) 284 (3.9%)213 (13%)124 (18.3%) Malignancy Type* Skin 5911081 Lymph 1454525 Other 586032 Type Not Reported 221121 * Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy. Other malignancies reported include: adenocarcinoma (2; 2; 1), bladder (2; 1; 0), lung (2; 4; 2), breast (1; 5; 4); prostate (0; 5; 3), cervical (1; 1; 1); liver (1; 1; 1). Numbers in parentheses represent the number of reported cases within each time period. ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

103. FREEDOM FROM MALIGNANCY For Adult Lung Recipients (Follow-ups: April 1994-June 2004) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982

104. ADULT LUNG TRANSPLANT RECIPIENTS: Cause Of Death (Deaths: January 1992- June 2004) CAUSE OF DEATH 0-30 Days (N = 1146) 31 Days - 1 Year (N = 1,717) >1 Year - 3 Years (N = 1,428) >3 Years - 5 Years (N = 800) >5 Years (N = 829) BRONCHIOLITIS 5 (0.4%)82 (4.8%)378 (26.5%)231 (28.9%)225 (27.1%) ACUTE REJECTION 63 (5.5%)35 (2.0%)25 (1.8%)4 (0.5%)5 (0.6%) LYMPHOMA 1 (0.1%)47 (2.7%)32 (2.2%)11 (1.4%)27 (3.3%) MALIGNANCY, OTHER 1 (0.1%)44 (2.6%)78 (5.5%)60 (7.5%)70 (8.4%) CMV 065 (3.8%)20 (1.4%)4 (0.5%)3 (0.4%) INFECTION, NON-CMV 245 (21.4%)639 (37.2%)352 (24.6%)162 (20.3%)150 (18.1%) GRAFT FAILURE 331 (28.9%)307 (17.9%)244 (17.1%)137 (17.1%)127 (15.3%) CARDIOVASCULAR 121 (10.6%)72 (4.2%)50 (3.5%)36 (4.5%)46 (5.5%) TECHNICAL 96 (8.4%)44 (2.6%)11 (0.8%)2 (0.3%)3 (0.4%) OTHER 283 (24.7%)382 (22.2%)238 (16.7%)153 (19.1%)173 (20.9%) ISHLT 2005 J Heart Lung Transplant 2005;24: 945-982